Eye Connect

What is Eye Connect?

Receiving a diagnosis of macular disease can be challenging. People tell us they feel many emotions ranging from disbelief, apprehension and even depression.

It’s normal to feel this way, and we’re here to help.

Introducing Eye Connect, your guide to living with macular disease.

For more than 20 years, we’ve been working for the approximately 1.9 million Australians living with macular disease, their families, and carers.

We developed Eye Connect in collaboration with patients, carers, and eye care professionals, to ensure you get the best care between visits to your optometrist or ophthalmologist. While Eye Connect is currently only available to people living with age-related macular degeneration, the service will be supporting other macular conditions in the future.

This free service focuses on three areas:

• Health information. We’ll provide you with evidence-based information about macular disease, and non-clinical support services to help you confidently manage your condition.
• Practical advice. Tips and guidance on things like nutrition for healthy eyes, immediate care after your appointment, daily living with reduced or low vision, and even transport advice.
• Emotional support. For some, a diagnosis of macular disease – or living with an eye condition – can be a difficult time. Our Eye Connect team can help you manage some of the worries and concerns you may have about your diagnosis and treatment. We can also connect you to peer support.

Eye Connect will provide support over an extended period, enabling you to better understand and manage life with macular disease. This support is available through phone, email, and through printed resources, depending on your preference.

Joining Eye Connect is easy. Complete the contact form and one of our friendly team will be in touch within two business days to get you started.

Eye Connect is proudly supported through the generosity of corporate sponsors and community donations. We wish to extend our thanks to the macular disease community, as well as Apellis, Novartis, and Roche in Australia.